New Collaboration to Assess Specificity of Postpartum Depression Biomarker Signature
Brisbane, Australia – March 11, 2026 – Ketim Technologies has initiated a new research collaboration with the Thompson Institute at the University of the Sunshine Coast to evaluate the specificity of its postpartum depression (PPD) biomarker signature.
Panel Participation at Women in Technology International Women’s Day 2026
Brisbane, Australia – March 8, 2026 – Dr. Clarissa Yates, Founder and CEO of Ketim Technologies, participated as an invited panellist at the 2026 International Women’s Day Breakfast hosted by Women in Technology in Brisbane.
Contributing to Queensland’s Biotech Ecosystem at Nucleate Australia Panel
Brisbane, Australia – March 3, 2026 – Dr. Clarissa Yates, Founder and CEO of Ketim Technologies, was invited to join a panel discussion hosted by Nucleate Australia in partnership with UniSC Innovation Centre.
AIIA Feature Highlights iAwards Journey and National Recognition
Brisbane, Australia – February 26, 2026 – Ketim Technologies has been featured by Australian Information Industry Association (AIIA) following its State and National wins at the 2025 iAwards.
Engagement with U.S. Consul General Strengthens Australia–U.S. Expansion Pathway
Brisbane, Australia – February 23, 2026 – Ketim Technologies was invited to participate in a private roundtable discussion with Jeremy Cornforth, U.S. Consul General, alongside selected founders and investors with active Australia–United States ties.
Industry Growth Program Completion Marks Key Commercial Milestone
Brisbane, Australia – February 19, 2026 – Ketim Technologies has successfully completed the 2025 Industry Growth Program (IGP), delivered by AusBiotech and funded by the Department of Industry, Science and Resources.
Ketim Technologies Awarded Advance Queensland Ignite Spark Grant to Progress Perinatal Mental Health Diagnostic
Brisbane, Australia – February 12, 2026 – Ketim Technologies has been awarded $75,000 through the Advance Queensland Ignite Spark Program to support the project titled “Industry Integration and Validation for Perinatal Mental Health Blood Test.”
North American Regulatory and Commercial Engagement Advances U.S. Validation Pathway
Brisbane, Australia – February 5, 2026 – Ketim Technologies has completed a three-week North American engagement tour spanning San Francisco, Ottawa, Wallingford (Connecticut), Minneapolis, and San Jose, advancing regulatory planning, manufacturing alignment, and U.S. validation strategy.
International PCT Patent Filed for Ketim’s Postpartum Depression Biomarker Technology
Brisbane, Australia – February 4, 2026 – Ketim Technologies has officially filed an international Patent Cooperation Treaty (PCT) application, marking a major milestone in protecting its proprietary biomarker technology for postpartum depression risk prediction.
Global Investor Engagement at RESI JPM 2026 Strengthens International Momentum
Brisbane, Australia – February 1, 2026 – Ketim Technologies participated in RESI JPM 2026 in San Francisco, engaging with global investors, strategic partners, and healthcare innovators during one of the world’s leading life sciences investment weeks.
Singapore Feature Highlights Founder’s Roots and Future Expansion into Asia
Brisbane, Australia – January 24, 2026 – Dr. Clarissa Yates, Ph.D., Founder and CEO of Ketim Technologies, has been featured in Singapore, reflecting on her heritage and the company’s future plans to expand its postpartum depression risk prediction platform into the region.
Ketim Founder Featured on Channel News Asia to Spotlight Maternal Mental Health Innovation
Brisbane, Australia – January 15, 2026 – Dr. Clarissa Yates, Ph.D., Founder and CEO of Ketim Technologies, has been featured by Channel News Asia (CNA), highlighting innovation in maternal mental health and the future of precision psychiatry.
Women’s Health and Artificial Intelligence: Advancing Precision in Perinatal Mental Health
Brisbane, Australia – January 6, 2026 – A recent editorial in Women’s Health and Artificial Intelligence published by JAMA Internal Medicine highlights the growing importance of applying artificial intelligence thoughtfully and equitably to address long-standing gaps in women’s health.
EmpowerTech x WiT Podcast Features Precision Psychiatry and Maternal Mental Health Innovation
Brisbane, Australia – January 4, 2026 – Following her recognition at the 2025 Women in Technology Awards, Dr. Clarissa Yates, Founder and CEO of Ketim Technologies, has been featured on the EmpowerTech x WiT Podcast in conversation with Iyari Cevallos.
2025 Awards Overview
Brisbane, Australia – January 3, 2026 –2025 has marked a year of significant national recognition for Ketim Technologies and its Founder and CEO, Dr. Clarissa Yates, with four major awards acknowledging innovation in AI-driven diagnostics and maternal mental health.
Second Independent Validation Study Initiated to Expand Prenatal Testing Window
Brisbane, Australia – January 2, 2026 – Ketim Technologies has commenced its second independent validation study of its signature protein panel for postpartum depression risk prediction.
Selected as Finalist for RESI JPM Innovator’s Pitch Challenge 2026
Brisbane, Australia – December 27, 2025 – Ketim Technologies has been shortlisted as a finalist in the RESI JPM Innovator’s Pitch Challenge, to be held during RESI JPM Week in January 2026.
Strategic Planning Milestone Marks 18 Months of Growth and Momentum
Brisbane, Australia – December 22, 2026 – Eighteen months after launch, Ketim Technologies has completed a comprehensive five-year strategic planning session, marking a significant milestone in the company’s evolution from early-stage concept to funded precision psychiatry venture.
Leadership Expansion Strengthens Operational and Commercial Strategy Following Pre-Seed Raise
Brisbane, Australia – December 11, 2026 – Following the successful close of its pre-seed funding round, Ketim Technologies has expanded its leadership team to accelerate clinical validation and commercial readiness.
Redefining Psychiatry Through Biology and Data
Brisbane, Australia – December 10, 2025 – A recent large-scale genomic study analysing data from more than one million individuals suggests that major psychiatric conditions may share underlying biological architectures, challenging traditional symptom-based diagnostic categories.